Pfizer, Inc. (PFE) Tops Q3 EPS by 7c; Raises Buyback Target to $7-$9B; Reaffirms Outlook
Tweet
Share
E-mail
Get Alerts PFE Hot Sheet
Price: $25.21 -2.74%
EPS Growth %: -12.8%
Financial Fact:
Research and development expenses: 1.88B
Today's EPS Names:
DTGI, CRMT, MAYS, More
EPS Growth %: -12.8%
Financial Fact:
Research and development expenses: 1.88B
Today's EPS Names:
DTGI, CRMT, MAYS, More
Join SI Premium – FREE
Pfizer, Inc. (NYSE: PFE) reported Q3 EPS of $0.62, $0.07 better than the analyst estimate of $0.55. Revenue for the quarter came in at $17.2 billion versus the consensus estimate of $16.43 billion.
Raises its buyback target to $7-$9 billion.
Reaffirms FY11 guidance.
Raises its buyback target to $7-$9 billion.
Reaffirms FY11 guidance.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Pfizer reaffirms 2026 guidance after CFO transition news
- John Wiley & Sons, Inc. (WLY) Tops Q4 EPS by 12c; offers outlook
- Accenture (ACN) Tops Q3 EPS by 8c, Misses on Revenue; Offers FY26 EPS Guidance
Create E-mail Alert Related Categories
Earnings, Guidance, Hot Earnings, Stock BuybacksSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
